RxDoctor Payments Data

Colin Vanhook

Neurology · New Orleans, LANPI 1831484153

Payments from drug & device makers

$1,195in general payments, 2019–2025

Across 68 payments — averaging $17.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$377
  • Jazz Pharmaceuticals Inc.$233
  • UCB, Inc.$168
  • Sunovion Pharmaceuticals Inc.$118
  • Amgen$79
  • SK Life Science, Inc.$64
  • plus $157 from 8 others

What the payments were for

  • Speaking & faculty fees$171%
  • Food & beverage$1,17999%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,195 in reported general payments places this provider in the 35th percentile of 225 neurology providers in Louisiana.

See all neurology providers in Louisiana

Medicare billing

Part B allowed, 2024
$54,315
Medicare patients
236
Services billed
418

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Vigabatrin12$223,313
FycompaPerampanel44$79,027
BriviactBrivaracetam11$60,705
Emgality SyringeGalcanezumab-Gnlm35$48,253
QuliptaAtogepant38$47,119
Clobazam156$41,114
Aimovig AutoinjectorErenumab-Aooe50$39,572
UbrelvyUbrogepant35$37,062
AptiomEslicarbazepine Acetate12$29,891
Emgality PenGalcanezumab-Gnlm43$29,814
Lamictal XrLamotrigine13$24,256
XcopriCenobamate12$15,803
Levetiracetam308$13,659
Nurtec OdtRimegepant Sulfate12$12,968
Lacosamide180$10,331

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$377$84,18273 claims
Eisai Inc.Fycompa$31$79,02744 claims
UCB, Inc.Briviact$168$60,70511 claims
Sunovion Pharmaceuticals Inc.Aptiom$118$29,89112 claims
SK Life Science, Inc.Xcopri$64$15,80312 claims
PfizerNurtec Odt$17$12,96812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 225 neurology providers in Louisiana.

Other neurology in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →